Kutatási jelek – Signal Engine

• Andreas Saltos, MD — NSCLC
• TP53 Allele Burden Sharpens Risk in Diffuse Large B‑Cell Lymphoma — Diffuse large B-cell lymphoma
• New stomach cancer treatment recommended by NICE after 'light-touch' assessment — Gastric cancer
• Does the PSA test for prostate cancer save lives? Gold-standard findings show surprising shift — Prostate cancer
• Novel Adenoid Cystic Carcinoma Drug Earns FDA Breakthrough Therapy Status — Adenoid cystic carcinoma
• Successfully Treated AML Patients May Hold the Key to New CAR T Cell Therapy — Pancreatic cancer
• Overview of clinical trials in CML - Recruiting trials | iCMLf — Chronic myeloid leukemia
• Metastatic Renal Cell Carcinoma: Which Patients Have the Best Outlook? — Renal cell carcinoma
• FDA Grants RMAT Designation to RZ-001 in Advanced Hepatocellular Carcinoma — Hepatocellular carcinoma
• Esophageal Cancer Workup: Approach Considerations, Imaging Studies, Staging — Esophageal cancer
• Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL) — Chronic lymphocytic leukemia
• U.S. Food and Drug Administration Accepts New Drug Application for Zipalertinib for the Treatment of Locally Advanced or Metastatic Non‑Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations — NSCLC
• Thyroid Cancer Clinical Trials - International Thyroid Oncology Group — Thyroid cancer
• TERN-701 Earns FDA Breakthrough Therapy Designation in Ph+ CML — NSCLC
• A New Possibility for Advanced Prostate Cancer — Prostate cancer
• Metastatic Ewing's Trial | Nationwide Children's Hospital — Ewing sarcoma
• Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC) — Renal cell carcinoma
• U.S. FDA Grants Priority Review to PADCEV® + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility — Bladder cancer
• CheckMate 743 Trial Update at 5 Years: New Insights on Mesothelioma Immunotherapy — Malignant pleural mesothelioma
• Uveal Melanoma — Melanoma